Search

Novo Nordisk A-S (Class B)

Closed

884.6 -0.17

Overview

Share price change

24h

Current

Min

883.8

Max

892.5

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+9.53 upside

Novo Nordisk A-S (Class B) Chart

Related News

7 Aug 2024, 10:13 UTC

Earnings

Novo Nordisk's Wegovy Sales Disappoint -- 2nd Update

7 Aug 2024, 06:58 UTC

Earnings

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge -- Update

7 Aug 2024, 06:10 UTC

Earnings

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge

3 Sept 2024, 11:09 UTC

Top News

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27 Aug 2024, 05:30 UTC

Top News

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14 Aug 2024, 12:01 UTC

Market Talk
Earnings

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9 Aug 2024, 11:30 UTC

Top News

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9 Aug 2024, 07:30 UTC

Market Talk

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8 Aug 2024, 15:44 UTC

Top News
Earnings

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

8 Aug 2024, 11:36 UTC

Market Talk
Earnings

Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk

8 Aug 2024, 07:16 UTC

Market Talk
Earnings

Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk

7 Aug 2024, 20:30 UTC

Top News

Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here's What to Expect. -- Barrons.com

7 Aug 2024, 16:39 UTC

Earnings

Novo Nordisk's Wegovy Sales Disappoint -- Update

7 Aug 2024, 15:30 UTC

Earnings
Acquisitions, Mergers, Takeovers

Novo Nordisk's Wegovy Sales Disappoint -- WSJ

7 Aug 2024, 14:22 UTC

Top News
Earnings

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7 Aug 2024, 12:28 UTC

Market Talk
Earnings

Novo Nordisk's Core Products Disappoint -- Market Talk

7 Aug 2024, 12:04 UTC

Earnings

Novo Nordisk Execs Were Speaking on a Call After 2Q Earnings

7 Aug 2024, 11:34 UTC

Earnings

Novo Nordisk US Head: As Wegovy Volumes Go Up, Prices Will Come Down

7 Aug 2024, 11:34 UTC

Earnings

Novo Nordisk CEO: When You Move Into New Sales Channels it Comes With a Discount

7 Aug 2024, 11:34 UTC

Earnings

Novo Nordisk CEO: Wegovy Now Covered in 20 States Through Medicaid

7 Aug 2024, 11:05 UTC

Market Talk
Earnings

Novo Nordisk Delivers Messy Quarter as Wegovy Misses The Mark -- Market Talk

7 Aug 2024, 10:55 UTC

Earnings

Stock Market Madness Highlights This Problem for -2-

7 Aug 2024, 10:55 UTC

Earnings

Stock Market Madness Highlights This Problem for Novo Nordisk and Super Micro. And 5 Other Things to Know Today. -- Barrons.com

7 Aug 2024, 09:07 UTC

Earnings
Hot Stocks

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7 Aug 2024, 08:55 UTC

Top News

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

7 Aug 2024, 07:32 UTC

Market Talk
Earnings

Novo Nordisk Wegovy Sales Disappoint -- Market Talk

7 Aug 2024, 05:45 UTC

Earnings

Novo Nordisk Declares Interim Dividend of DKK3.50

7 Aug 2024, 05:44 UTC

Earnings

Novo Nordisk 2Q Gross Margin 84.9% Vs 85.5%, Op Margin 38.1% Vs 44.0%

7 Aug 2024, 05:40 UTC

Earnings

Novo Nordisk 2Q Wegovy Drug Sales DKK11.66B Vs DKK7.52B

7 Aug 2024, 05:38 UTC

Earnings

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints, Related Drug Shortage Notifications

Novo Nordisk A-S (Class B) Forecast

Price Target

By TipRanks

9.53% upside

12 Months Forecast

Average 1,162.73 DKK  9.53%

High 1,550 DKK

Low 720 DKK

Based on 11 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S (Class B) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

7

Buy

2

Hold

2

Sell